Breast Cancer-Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual

Area of Science:

• Oncology
• Cancer Staging
• Biomarkers

Background:

• The American Joint Committee on Cancer (AJCC) eighth edition revision for breast cancer staging was developed by experts.
• Previous staging relied solely on anatomic factors (TNM).
• There was a recognized need to integrate prognostic biologic factors.

Purpose of the Study:

• To revise the AJCC TNM staging system for breast cancer.
• To incorporate biologic factors into the existing staging framework.
• To enhance prognostic accuracy and clinical utility.

Main Methods:

• Multidisciplinary expert panel review.
• Incorporation of tumor grade, proliferation rate, hormone receptor (estrogen/progesterone) status, and HER2 expression.
• Inclusion of gene expression prognostic panels and commercially available gene-based assays.
• Adherence to AJCC levels of evidence and guidelines.

Main Results:

• The eighth edition TNM staging system now integrates anatomic factors with biologic markers.
• Tumor grade, hormone receptor status, and HER2 amplification are key additions.
• Gene expression assays and biomarkers like Oncotype DX recurrence scores influence prognosis and stage.
• The revised system offers increased precision and flexibility.

Conclusions:

• The eighth edition provides a flexible platform for breast cancer prognostic classification.
• Integration of biomarkers enhances traditional anatomic staging.
• The AJCC TNM staging system remains the global standard for breast cancer staging.
• Future online updates will ensure continued relevance.